KALDENN
LIVE

Serial Number

79403077

Owner

NAOGEN PHARMA

Attorney

Jeffrey H. Handelsman

Filing Date

May 14, 2024

Add to watchlist:

No watchlists yet
View on USPTO

KALDENN Trademark

Serial Number: 79403077 • Registration: 7885584

KALDENN is a trademark filed by NAOGEN PHARMA on May 14, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

NAOGEN PHARMA

rue du Moulin de la Rousselière

Entity Type: 99

Trademark Details

Filing Date

May 14, 2024

Registration Date

August 12, 2025

Published for Opposition

June 24, 2025

Goods & Services

Radiopharmaceutical generators for medical use being medical generators specially adapted for medical, diagnostic and therapeutic purposes, namely for use in the production and transportation of nuclear medicines, radioactive substances for medical purposes, radiopharmaceutical products and radiopharmaceutical medicines; radioactive and radiopharmaceutical product generators for medical use being medical generators specially adapted for medical nuclear medicine purposes, namely for use in the production and transportation of nuclear medicines, radioactive substances for medical purposes, radiopharmaceutical products and radiopharmaceutical medicines; rubidium-82 generators for medical use being medical generators specially adapted for medical, diagnostic and therapeutic purposes, namely for use in the production and transportation of nuclear medicines, radioactive substances for medical purposes, radiopharmaceutical products and radiopharmaceutical medicines; medication injectors for medical use, namely, medical fluid injectors and injection devices for pharmaceuticals and radiopharmaceutical products; radiopharmaceutical medicine injectors being injection devices; radioactive and radiopharmaceutical product injectors for medical use being injection devices for pharmaceuticals, radioactive products and radiopharmaceutical products; automatic injectors being injection devices for administering radiopharmaceutical products; injectors of rubidium-82 to patients for medical use, namely, medical fluid injectors and injection devices for pharmaceuticals, radioactive products and radiopharmaceutical products; magnetic resonance tomography apparatus, namely, magnetic resonance imaging apparatus for medical purposes; medical equipment, namely, computed tomography apparatus; tomographic scanners for nuclear medicine, namely, X-ray CT scanners; medical apparatus for diagnosing suspected heart attacks

Chemical substances, chemical materials and chemical products for use in medicine production, namely, chemical additives and active chemical ingredients for use in the manufacture of radiopharmaceutical preparations and pharmaceuticals for detecting and treating coronary diseases and coronary artery diseases; chemical substances, chemical preparations and chemical products for use in radiopharmaceutical product manufacture, namely, chemical additives and active chemical ingredients for use in the manufacture of radiopharmaceutical preparations and pharmaceuticals for detecting and treating myocardial ischaemia; active chemical ingredients for use in manufacture of radiopharmaceutical preparations against cancer; diagnostic preparations for scientific use or for research; diagnostic reagents for scientific use or for research; radioactive preparations for laboratory use for scientific purposes; contrast agents for molecular imaging other than for medical use; rubidium; strontium

Radiopharmaceutical products, namely, radioactive substances for use in nuclear medicine; radioactive products for medical use, namely, radioactive pharmaceutical preparations for use in vivo diagnostic or therapeutic use; radioactive substances for medical use; isotopes for medical use; radiopharmaceutical preparations for medical use made from radiopharmaceutical generators, namely, for the detection and treatment of cancers, coronary diseases, coronary artery diseases, heart diseases and myocardial ischaemia; diagnostic radiopharmaceutical preparations; reagents and substances for medical diagnostic purposes; diagnostic biomarking reagents for medical use; contrast products being media for use with medical imaging equipment; cardiovascular medicines used in myocardial infarction treatment; contrast agents being media for use with molecular imaging equipment for medical use

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 26, 2026 FINO
NEW REPRESENTATIVE AT IB RECEIVED
Mar 19, 2026 NREP
FINAL DISPOSITION NOTICE SENT TO IB
Feb 21, 2026 FICS
FINAL DISPOSITION PROCESSED
Feb 21, 2026 FIMP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Feb 12, 2026 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 27, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jan 27, 2026 OPNR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 12, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 12, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 12, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 24, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jun 24, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 18, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 21, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 15, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 15, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 15, 2025 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 15, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
May 15, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 15, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 15, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 15, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 15, 2025 COAR
REFUSAL PROCESSED BY IB
Dec 29, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 12, 2024 RFCS
REFUSAL PROCESSED BY MPU
Dec 12, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Nov 28, 2024 RFCR
NON-FINAL ACTION WRITTEN
Nov 27, 2024 CNRT
ASSIGNED TO EXAMINER
Nov 26, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 3, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 3, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 29, 2024 REPR